Cellular and humoral influenza-specific immune response upon vaccination in patients with common variable immunodeficiency and unclassified antibody deficiency

Vaccine

Volumn 34, Issue 21, 2016, Pages 2417-2423

  Hanitsch, Leif G ^a   Löbel, Madlen ^a   Mieves, Jan Florian ^a   Bauer, Sandra ^a   Babel, Nina ^a,b   Schweiger, Brunhilde ^c   Wittke, Kirsten ^a   Grabowski, Patricia ^a   Volk, Hans Dieter ^a   Scheibenbogen, Carmen ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c ROBERT KOCH INSTITUTE   (Germany)

Author keywords

CVID; Cytokines; Influenza vaccination; T cell response; Unclassified antibody deficiency

Indexed keywords

CD40 LIGAND; GAMMA INTERFERON; INFLUENZA VACCINE; INTERLEUKIN 2; PNEUMOCOCCUS VACCINE; TUMOR NECROSIS FACTOR ALPHA; INACTIVATED VACCINE; TUMOR NECROSIS FACTOR; VIRUS ANTIBODY;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; COMMON VARIABLE IMMUNODEFICIENCY; CONTROLLED STUDY; CYTOKINE RESPONSE; FEMALE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; HUMORAL IMMUNE DEFICIENCY; HUMORAL IMMUNITY; INFLUENZA VACCINATION; MALE; PRIORITY JOURNAL; SEASONAL INFLUENZA; T LYMPHOCYTE; UNCLASSIFIED ANTIBODY DEFICIENCY; BLOOD; IMMUNE DEFICIENCY; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); INFLUENZA, HUMAN; MIDDLE AGED; NORMAL HUMAN; ORTHOMYXOVIRIDAE; VACCINATION; VIROLOGY;

ADULT; ANTIBODIES, VIRAL; CD40 LIGAND; COMMON VARIABLE IMMUNODEFICIENCY; FEMALE; HEALTHY VOLUNTEERS; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; INTERFERON-GAMMA; INTERLEUKIN-2; MALE; MIDDLE AGED; ORTHOMYXOVIRIDAE; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA; VACCINATION; VACCINES, INACTIVATED;

EID: 84962834110     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.03.091     Document Type: Article

References (18)

1. Schmidt R.E., Ochs H.D. 7th international immunoglobulin conference: immunodeficiencies. Clin Exp Immunol 2014, 178(Suppl. 1):3-4.
2. Cunningham-Rundles C. How I treat common variable immune deficiency. Blood 2010, 116:7-15.
3. Driessen G.J., Dalm V.A., van Hagen P.M., Grashoff H.A., Hartwig N.G., van Rossum A.M., et al. Common variable immunodeficiency and idiopathic primary hypogammaglobulinemia: two different conditions within the same disease spectrum. Haematologica 2013, 98:1617-1623.
4. Quinti I., Soresina A., Guerra A., Rondelli R., Spadaro G., Agostini C., et al. Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study. J Clin Immunol 2011, 31:315-322.
5. Chase N.M., Verbsky J.W., Hintermeyer M.K., Waukau J.K., Tomita-Mitchell A., Casper J.T., et al. Use of combination chemotherapy for treatment of granulomatous and lymphocytic interstitial lung disease (GLILD) in patients with common variable immunodeficiency (CVID). J Clin Immunol 2013, 33:30-39.
6. de Gracia J., Vendrell M., Alvarez A., Pallisa E., Rodrigo M.J., de la Rosa D., et al. Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency. Int Immunopharmacol 2004, 4:745-753.
7. Plebani A., Fischer M.B., Meini A., Duse M., Thon V., Eibl M.M. T cell activity and cytokine production in X-linked agammaglobulinemia: implications for vaccination strategies. Int Arch Allergy Immunol 1997, 114:90-93.
8. + T cells in human X-linked agammaglobulinemia. Blood 2002, 99:2131-2137.
9. Morales-Aza B., Glennie S.J., Garcez T.P., Davenport V., Johnston S.L., Williams N.A., et al. Impaired maintenance of naturally acquired T-cell memory to the meningococcus in patients with B-cell immunodeficiency. Blood 2009, 113:4206-4212.
10. Amedei A., Romagnani C., Benagiano M., Azzurri A., Fomia F., Torrente F., et al. Preferential Th1 profile of T helper cell responses in X-linked (Bruton's) agammaglobulinemia. Eur J Immunol 2001, 31:1927-1934.
11. Principi N., Esposito S. Vaccine use in primary immunodeficiency disorders. Vaccine 2014, 32:3725-3731.
12. van Assen S., de Haan A., Holvast A., Horst G., Gorter L., Westra J., et al. Cell-mediated immune responses to inactivated trivalent influenza-vaccination are decreased in patients with common variable immunodeficiency. Clin Immunol 2011, 141:161-168.
13. + Th1-cell responses in hypogammaglobulinaemic patients: four case reports. Scand J Immunol 2011, 74:210-218.
14. Warnatz K., Schlesier M. Flowcytometric phenotyping of common variable immunodeficiency. Cytometry B Clin Cytom 2008, 74:261-271.
15. Meyer S., Adam M., Schweiger B., Ilchmann C., Eulenburg C., Sattinger E., et al. Antibody response after a single dose of an AS03-adjuvanted split-virion influenza A (H1N1) vaccine in heart transplant recipients. Transplantation 2011, 91:1031-1035.
16. Products, EAftEoM, Note for guidance on harmonization of requirements for influenza vaccines (CPMP/BWP/214/96), 1997.
17. Talbot H.K., Griffin M.R., Chen Q., Zhu Y., Williams J.V., Edwards K.M. Effectiveness of seasonal vaccine in preventing confirmed influenza-associated hospitalizations in community dwelling older adults. J Infect Dis 2011, 203:500-508.
18. Talbot H.K., Zhu Y., Chen Q., Williams J.V., Thompson M.G., Griffin M.R. Effectiveness of influenza vaccine for preventing laboratory-confirmed influenza hospitalizations in adults, 2011-2012 influenza season. Clin Infect Dis 2013, 56:1774-1777.